748709
Last Update Posted: 2025-02-11
Recruiting has ended
All Genders accepted | 18 Years-99 Years |
20 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
This is a Phase II open-label exploratory trial of BIBW 2992 administered to patients with tumors of various histologies found to possess EGFR and/or HER2 gene amplification, or EGFR activating mutations.
Eligibility
Relevant conditions:
Neoplasms
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov